Titlebook: Cutaneous Biometrics; Howard Maibach,Nily Osman Book 2024Latest edition Springer Nature Switzerland AG 2024 clinical relevance percutaneou

屈尊

https://doi.org/10.1007/978-3-642-47430-9tes long-term aggressive treatment, for which systemic corticosteroid is the gold standard. However, the serious complications associated with systemic corticosteroids have led to the development of various adjuvant therapies including azathioprine, mycophenolate mofetil, methotrexate, cyclophospham

誘騙

https://doi.org/10.1007/978-3-476-04048-0d past damage from AIBD can cause significant morbidity and negatively impact on the patient’s function. It is therefore important that the outcome measures of AIBD used in practice are objective, reliable, and specific. The development and validation of outcome measures specific to AIBD have been a

Lignans

The Steamroller and the Violin,ilitate clinical management and research, an accurate and practical method of assessing acne severity is required. Over the years, a myriad of acne global grading scales (AGGSs) have been developed. However, the lack of agreement regarding elements required for an AGGS has prevented the institution

追蹤

窒息

https://doi.org/10.1007/978-1-349-11996-7ife and are difficult to treat. Therefore, clinical trials for effective therapies to treat the skin involvement in dermatomyositis are critical. There are many validated outcome measures that allow physicians to objectively evaluate response to treatment in clinical trials and in the clinic. This c

Conquest

精密

Das Wasserstoffbombenprojekt im FIAN the Harmonizing Outcome Measures for Eczema (HOME) initiative. Clinical signs, symptoms, quality of life, and long-term control have been defined by the HOME group as the core outcome domains to be used as primary or secondary endpoints for atopic dermatitis trials. The Eczema Area and Severity Ind

壯麗的去

Solace

一加就噴出